Colon signet ring cell adenocarcinoma
diseaseOn this page
Also known as colonic signet Ring cell adenocarcinomasignet Ring cell adenocarcinoma of colonsignet Ring cell adenocarcinoma of the colonsignet Ring cell colon adenocarcinoma
Summary
Colon signet ring cell adenocarcinoma (MONDO:0002495) is a disease and 2 clinical trials. Top therapeutic interventions include cetuximab. A subtype of colon adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 2
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | colon signet ring cell adenocarcinoma |
| Mondo ID | MONDO:0002495 |
| DOID | DOID:3033 |
| NCIT | C7967 |
| UMLS | C1707436 |
| MedGen | 313039 |
| Anatomy (UBERON) | UBERON:0001155 |
| Is cancer (heuristic) | no |
Also known as: colon signet Ring cell adenocarcinoma · colonic signet Ring cell adenocarcinoma · signet Ring cell adenocarcinoma of colon · signet Ring cell adenocarcinoma of the colon · signet Ring cell colon adenocarcinoma
Data availability: 1 cell line.
Disease family
This is a subtype of colon adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: human disease › disease by body system or component › digestive system disorder › intestinal disorder › large intestine disorder › colonic disorder › colonic neoplasm › malignant colon neoplasm › colon carcinoma › colon adenocarcinoma › colon signet ring cell adenocarcinoma
Related subtypes (4): colon medullary carcinoma, submucosal invasive colon adenocarcinoma, colon mucinous adenocarcinoma, cecum adenocarcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 2.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01802320 | PHASE2 | COMPLETED | Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery |
| NCT01198535 | PHASE1 | TERMINATED | Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CETUXIMAB | 4 | 1 |
Related Atlas pages
- Drugs: Cetuximab